Europe's medicines watchdog has approved a Covid jab by US-based Novavax, which uses a more conventional technology that the biotech firm hopes will reduce vaccine hesitancy. In a statement released this Monday,Â the European Medicines Agency said: "EMA has recommended granting a conditional marketing authorisation for Novavax's Covid-19 vaccine Nuvaxovid to prevent Covid-19 in people from 18 years of age." Novavax is theÂ fifth vaccineÂ to be recommended for authorisation in the European Union, as the Omicron variant spreads across the bloc. The US-developedÂ vaccine is expected toÂ start rolling out its deliveries to the European Union inÂ the first quarter of 2022. â€¼ï¸ EMA recommends Nuvaxovid, the #COVID19vaccine developed by #Novavax, for authorisation in the ğŸ‡ªğŸ‡º, to prevent #COVID19 in people from 18 years of age. #HealthUnion ğŸ‘‰ https://t.co/C0CrY8Jhih pic.twitter.com/bFDwTnh4Zf Data from two large studies showed the vaccine has anÂ efficacy of around 90%, the EMA said, adding that there was currently limited data on itsÂ efficacy against some variants of concern, including Omicron. The regulator added: "After a thorough evaluation, EMA's human medicinesÂ committee concluded by consensus that the data on theÂ vaccine were robust and met the EU criteria for efficacy, safetyÂ and quality." Covid-19 infections have broken records in parts of EuropeÂ in recent weeks, with governments and researchers scrambling toÂ bolster defences against the fast-spreading Omicron coronavirusÂ variant, prompting renewed curbs ahead of the holidays. Europe steps up vaccination of young kids as Omicron gains ground  	Moderna boss warns vaccines will struggle against Omicron variant The endorsement for the two-dose vaccine, branded Nuvaxovid,Â comes well ahead of possible authorisation in the United States,Â where Novavax has had to resolve manufacturing issues andÂ expects to file for approval by the end of the year. The regulatory process in the EU has taken longer thanÂ expected too. The European Medicines Agency started a rollingÂ review of the data in February. Novavax and the EU reached a preliminary deal in DecemberÂ 2020 for the supply of the vaccine, but due to regulatory andÂ production issues the final contract for up to 200 million dosesÂ was only signed in August. The company said on Monday it would start shipping vaccinesÂ to the EU's 27 member states in January. The shot received its first regulatory greenlight inÂ Indonesia last month and is currently awaiting approval in Japan. Daily newsletterReceive essential international news every morning Keep up to date with international news by downloading the RFI app